Prescription pattern of inhalational medications for chronic obstructive pulmonary disease in India: insights from cross-sectional survey of pulmonologists across India

Vishnu Sharma M.; Parthiv A. Shah; Abhinav Guliani; Soumya Das; Ashish S. Deshmukh; Kunal Khobragade; Nitinkumar S. Doshi

doi:10.18203/2320-6012.ijrms20242220

Authors

Vishnu Sharma M. Department of Respiratory Medicine, A. J. Institute of Medical Sciences and Research Centre, Mangalore, Karnataka, India
Parthiv A. Shah Consultant Chest Physician, Mumbai, Maharashtra, India
Abhinav Guliani Department of Chest Medicine, Sir Ganga Ram Hospital and Ganga Ram Institute of Post Graduate Medical Education and Research, New Delhi, India
Soumya Das Department of Chest Medicine, Sir Ganga Ram Hospital and Ganga Ram Institute of Post Graduate Medical Education and Research, New Delhi, India
Ashish S. Deshmukh Consultant Pulmonologist, Oriion Citicare Superspeciality Hospital, Osmanpura, Aurangabad, Maharashtra, India
Kunal Khobragade Medical Affairs, Mankind Pharma Ltd, Navi Mumbai, Maharashtra, India
Nitinkumar S. Doshi Medical Affairs, Mankind Pharma Ltd, Navi Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20242220

Keywords:

COPD, Inhalational medications, Prescription pattern, Survey, Triple drug therapy

Abstract

Background: Treatment of COPD depends on disease severity, phenotype and exacerbation risk. Inhaled medications are the treatment of choice in COPD. We undertook this survey to find the most commonly prescribed inhalational medication in COPD as per the severity of the disease.

Methods: It was a cross-sectional questionnaire-based survey of pulmonologists in real-world clinical practice settings conducted across India.

Results: The participants included 806 pulmonologists across India. Seventy-five per cent of pulmonologists ranked symptom relief, reduction in the frequency of exacerbations and improvement in lung function as the most important treatment targets. In COPD patients falling under GOLD group A, the treatment choice by pulmonologists in descending rank order was fomroterol/glycopyrronium (32%), ipratropium (38%), and tiotropium (30%) and for gold group B, this was fomroterol/glycopyrronium (34%), followed by indacaterol/glycopyrronium (26%) and tiotropium/formoterol (40%). In the GOLD group E, triple therapy (formoterol/glycopyrronium/budesonide) was preferred by 41% of pulmonologists. In the frequent exacerbator, predominant emphysema, chronic bronchitis and concomitant asthma phenotype, 44%, 38%, 46% and 32% of pulmonologists ranked formoterol/ glycopyrronium/budesonide as their preferred 1st therapy, respectively. Among COPD patients with cardiovascular disease (CVD) comorbidity, 31% of pulmonologists selected formoterol/glycopyrronium/budesonide as 1^st-preference drug therapy. Similar results were obtained for COPD patients with metabolic syndrome comorbidity.

Conclusions: For the management of COPD patients, pulmonologists predominantly preferred a triple drug combination of formoterol/glycopyrronium/budesonide in GOLD group E and also in patients with cardiovascular and metabolic comorbidities. Fomroterol/glycopyrronium was the most preferred combination for GOLD group A and GOLD group B.

Metrics

Metrics Loading ...

References

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2023. Available from: https://goldcopd.org/2023-gold-report-2/. Accessed on 1 December 2023.

Roy DA, Aggarwal P, Kalaivani M, Gupta SK. Prevalence of chronic obstructive pulmonary disease in India: a systematic review and meta-analysis. Lung India. 2021;38(6):506-13.

Verma A, Gudi N, Yadav UN, Roy MP, Mahmood A, Nagaraja R, et al. Prevalence of COPD among population above 30 years in India: a systematic review and meta-analysis. J Glob Health. 2021;11:04038.

Global Burden of Diseases. Institute for Health Metrics and Evaluation.Viz Hub. Available from: https://vizhub.healthdata.org/gbd-compare/. Accessed on 16 September 2023.

Vanfleteren LEGW, Ullman A, Nordenson A, Andersson A, Andelid K, Fabbri LM. Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box. ERJ Open Res. 2019;5(1):185-2018.

Koul PA. Chronic obstructive pulmonary disease: Indian guidelines and the road ahead. Lung India. 2013;30(3):175-7.

Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20:1-5.

Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671-80.

Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35-48.

Aisanov Z, Bai C, Bauerle O, Colodenco FD, Feldman C, Hashimoto S, et al. Primary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the world. Int J Chron Obstruct Pulmon Dis. 2012;7:271-82.

COPD: Tracking Perceptions of Physicians Who Diagnose and Treat COPD (2017), NHLBI Publications and Resources. Available from: https://www.nhlbi.nih.gov/resources/copd-tracking-perceptions-physicians-who-diagnose-and-treat-copd-2017. Accessed on 1 December 2023.

Montuschi P. Pharmacological treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2006;1(4):409-23.

Laforest L, Denis F, Van Ganse E, Ritleng C, Saussier C, Passante N, et al. Correlates of adherence to respiratory drugs in COPD patients. Prim Care Respir J. 2010;19(2):148e54.

Slack RJ, Barrett VJ, Morrison VS, Sturton RG, Emmons AJ, Ford AJ, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013;344:218-30.

Cazzola M, Beeh KM, Price D, Roche N. Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD. Pulm Pharmacol Ther. 2015;31:68-78.

Braghiroli A, Braido F, Piraino A, Rogliani P, Santus P, Scichilone N. Day and night control of copd and role of pharmacotherapy: a review. Int J Chron Obstruct Pulmon Dis. 2020;15:1269-85.

Donohue JF. Minimal clinically important differences in COPD lung function. COPD J Chron Obstruct Pulmon Dis. 2005;2(1):111-24.

Loke YK, Singh S. Risk of acute urinary retention associated with inhaled anticholinergics in patients with chronic obstructive lung disease: systematic review. Ther Adv Drug Saf. 2013;4:19-26.

Durham MC. Tiotropium (Spiriva): a once-daily inhaled anticholinergic medication for chronic obstructive pulmonary disease. Bayl Univ Med Cent Proc. 2004;17(3):366-73.

Jayanthi N, Krishnan K, Sudhir M, Girija S, Nishi PA. Comparative study on the effectiveness of glycopyrrolate/formoterol versus tiotropium/ formoterol in patients with chronic obstructive pulmonary disease. Contemp Clin Trials Commun. 2022;28:100931.

Kaushal M, Shah PS, Shah AD, Francis SA, Patel NV, Kothari KK. Chronic obstructive pulmonary disease and cardiac comorbidities: A cross-sectional study. Lung India. 2016;33(4):404-9.

Priyanka A, Upasana B. Prevalence of cardiovascular comorbidities in patients with chronic obstructive pulmonary disease in suburban areas of south-west India. Asian J Pharm Clin Res. 2022;15(5).

Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005;128:2068-75.

Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med. 2000;160:2653-8.

Dave L, Garde S, Ansari OA, Shrivastava N, Sharma VK. A study of association between metabolic syndrome and COPD. J Evol Med Dent Sci. 2014;3:6183-8.

Olschewski H, Canepa M, Kovacs G. Pulmonary and cardiac drugs: clinically relevant interactions. Herz. 2019;44(6):517-521.

Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, et al. Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473-9.

Chapman KR, Beeh KM, Beier J, Bateman ED, D'Urzo A, Nutbrown R, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med. 2014;14:4.